VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 330 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2017. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,958,000 | +35.3% | 94,300 | -6.7% | 0.06% | +12.0% |
| Q3 2017 | $1,447,000 | +16.7% | 101,100 | +40.8% | 0.05% | +47.1% |
| Q2 2017 | $1,240,000 | +350.9% | 71,800 | +187.2% | 0.03% | +385.7% |
| Q1 2017 | $275,000 | -85.7% | 25,000 | -81.1% | 0.01% | -88.1% |
| Q4 2016 | $1,923,000 | +141.3% | 132,500 | +307.7% | 0.06% | +247.1% |
| Q3 2016 | $797,000 | -60.2% | 32,500 | -67.4% | 0.02% | -55.3% |
| Q2 2016 | $2,005,000 | -40.2% | 99,600 | -21.9% | 0.04% | -62.7% |
| Q1 2016 | $3,355,000 | +87.5% | 127,600 | +625.0% | 0.10% | +112.5% |
| Q4 2015 | $1,789,000 | -18.0% | 17,600 | +1.7% | 0.05% | +71.4% |
| Q2 2014 | $2,181,000 | -74.7% | 17,300 | -73.5% | 0.03% | -74.5% |
| Q1 2014 | $8,607,000 | – | 65,300 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |